Rivastigmine for ECT-induced cognitive adverse effects in late life depression (RECALL study): A multicenter, randomized, double blind, placebo-controlled, cross-over trial in patients with depression aged 55 years or older: Rationale, objectives and methods

Marieke J. Henstra, Thomas C. Feenstra, Rob M. Kok, Harm-Pieter Spaans, Eric van Exel, Annemiek Dols, Mardien Oudega, Anton C. M. Vergouwen, Adriano van der Loo, Pierre M. Bet, Stephan A. Loer, Merijn Eikelenboom, Pascal Sienaert, Simon Lambrichts, Filip Bouckaert, Judith E. Bosmans, Nathalie van der Velde, Aartjan T. F. Beekman, Max L. Stek, Didi Rhebergen

Open source

DOI: 10.3389/fpsyt.2022.953686
Published: 2022-07-15
Container: Frontiers in Psychiatry
Publisher: Frontiers Media SA
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fpsyt.2022.953686,
  title = {Rivastigmine for ECT-induced cognitive adverse effects in late life depression (RECALL study): A multicenter, randomized, double blind, placebo-controlled, cross-over trial in patients with depression aged 55 years or older: Rationale, objectives and methods},
  author = {Marieke J. Henstra and Thomas C. Feenstra and Rob M. Kok and Harm-Pieter Spaans and Eric van Exel and Annemiek Dols and Mardien Oudega and Anton C. M. Vergouwen and Adriano van der Loo and Pierre M. Bet and Stephan A. Loer and Merijn Eikelenboom and Pascal Sienaert and Simon Lambrichts and Filip Bouckaert and Judith E. Bosmans and Nathalie van der Velde and Aartjan T. F. Beekman and Max L. Stek and Didi Rhebergen},
  year = {2022},
  journal = {Frontiers in Psychiatry},
  doi = {10.3389/fpsyt.2022.953686},
  url = {https://doi.org/10.3389/fpsyt.2022.953686}
}

RIS

TY  - JOUR
TI  - Rivastigmine for ECT-induced cognitive adverse effects in late life depression (RECALL study): A multicenter, randomized, double blind, placebo-controlled, cross-over trial in patients with depression aged 55 years or older: Rationale, objectives and methods
AU  - Marieke J. Henstra
AU  - Thomas C. Feenstra
AU  - Rob M. Kok
AU  - Harm-Pieter Spaans
AU  - Eric van Exel
AU  - Annemiek Dols
AU  - Mardien Oudega
AU  - Anton C. M. Vergouwen
AU  - Adriano van der Loo
AU  - Pierre M. Bet
AU  - Stephan A. Loer
AU  - Merijn Eikelenboom
AU  - Pascal Sienaert
AU  - Simon Lambrichts
AU  - Filip Bouckaert
AU  - Judith E. Bosmans
AU  - Nathalie van der Velde
AU  - Aartjan T. F. Beekman
AU  - Max L. Stek
AU  - Didi Rhebergen
PY  - 2022
JO  - Frontiers in Psychiatry
DO  - 10.3389/fpsyt.2022.953686
UR  - https://doi.org/10.3389/fpsyt.2022.953686
ER  -

APA

Henstra, M. J., Feenstra, T. C., Kok, R. M., Spaans, H., Exel, E. V., Dols, A., Oudega, M., Vergouwen, A. C. M., Loo, A. V. D., Bet, P. M., Loer, S. A., Eikelenboom, M., Sienaert, P., Lambrichts, S., Bouckaert, F., Bosmans, J. E., Velde, N. V. D., Beekman, A. T. F., Stek, M. L., & Rhebergen, D. (2022). Rivastigmine for ECT-induced cognitive adverse effects in late life depression (RECALL study): A multicenter, randomized, double blind, placebo-controlled, cross-over trial in patients with depression aged 55 years or older: Rationale, objectives and methods. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2022.953686

Source records

crossref · retrieved 2026-09-25T00:15:11.828Z